Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status:
Terminated
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Giving erlotinib hydrochloride before surgery may make the tumor
smaller and reduce the amount of normal tissue that needs to be removed. This phase II trial
is studying how well erlotinib hydrochloride works in treating patients with pancreatic
cancer that can be removed by surgery